Associated Papers
Concurrent genomic assessment of circulating tumour cells and ctDNA to guide therapy in metastatic breast cancer.
Allsopp RC et al.
Bmc Cancer, 2025
41351070 (PubMed )
Supplement: 12885_2025_15187_MOESM1_ESM.zip › Supp_Table_1.xlsx › Sheet1
HER3 V104 mutations regulate cell signaling, growth, and drug sensitivity in cancer.
Mishra R et al.
Molecular Carcinogenesis, 2024
Pathogenic HER3 dimerization domain mutations create a structural bias towards un-conventional EGFR-HER3 signalling axis in breast cancer.
Dey P et al.
International Journal of Biological Macromolecules, 2023
Prevalence and role of HER2 mutations in cancer.
Cocco E et al.
Pharmacology & Therapeutics, 2019
Targeted mutation detection in breast cancer using MammaSeq™.
Smith NG et al.
Breast Cancer Research : Bcr, 2019
30736836 (PubMed )
Supplement: 13058_2019_1102_MOESM2_ESM.xlsx › Sheet1
Determination of somatic oncogenic mutations linked to target-based therapies using MassARRAY technology.
Ibarrola-Villava M et al.
Oncotarget, 2016
26968814 (PubMed )
Supplement: oncotarget-07-22543-s001.pdf
Comprehensive molecular portraits of human breast tumours.
Unknown Author
Nature, 2012
23000897 (PubMed )
Supplement: NIHMS393293-supplement-4.xls › Sheet_1
Select a paper to view details